Methotrexate Use in SLE Patients with Baseline Pancytopenia

Introduction to Methotrexate Contraindications

The European League Against Rheumatism recommends continuing steroids as monotherapy while addressing the underlying cause of pancytopenia in SLE patients with baseline pancytopenia 1, 2
The American College of Rheumatology suggests performing baseline workup including CBC, liver function tests, creatinine, and albumin to assess whether the pancytopenia improves with steroid treatment alone 1

The British Society for Rheumatology recommends considering methotrexate as a steroid-sparing agent in SLE patients once pancytopenia resolves with steroid therapy 1, 3
The European League Against Rheumatism suggests that methotrexate (7.5-20 mg/week) combined with steroids in SLE leads to significantly more prednisone dose reduction and fewer skin and joint flares, though with increased risk of adverse events 3, 4

The American College of Rheumatology recommends that CBC must be performed every 1-1.5 months until a stable dose is reached, then every 1-3 months thereafter in SLE patients on methotrexate therapy 1, 2
The European League Against Rheumatism suggests that methotrexate should be stopped immediately if there is a significant drop in blood counts, and leucovorin rescue therapy should be initiated promptly 1
The British Society for Rheumatology recommends folic acid supplementation of at least 5 mg per week to reduce hematologic and gastrointestinal toxicity in SLE patients on methotrexate therapy 1, 2

The American College of Rheumatology recommends considering hydroxychloroquine or azathioprine as safer alternatives for SLE arthritis in the setting of persistent pancytopenia 5, 6
The European League Against Rheumatism suggests that leflunomide may be an alternative DMARD in cases of contraindication or intolerance to methotrexate in inflammatory arthritis, though its safety profile in baseline pancytopenia is also concerning 5, 6